Table 2 Subgroups analysis of the primary outcomes that showed in-between-study heterogeneity
Item | Parameter | Studies | Patients | SMD | P | I2 % (model) |
|---|---|---|---|---|---|---|
Mode of administration | ||||||
NIHSS (3 months) | IA | 3 | 107 | − 0.64 [− 1.03, − 0.25] | 0.001a | 0 (F) |
IV | 2 | 150 | 1.35 [0.97, 1.72] | < 0.001a | 0 (F) | |
BI (3 months) | IA | 3 | 79 | − 0.33 [− 0.90, 0.24] | 0.26 | 34 (F) |
IV | 2 | 70 | 2.97 [2.23, 3.71] | < 0.001a | 0 (F) | |
BI (6 months) | IA | 4 | 119 | 1.37 [− 0.61, 3.34] | 0.18 | 95 (R) |
IV | 2 | 150 | 1.01 [− 0.87, 2.88] | 0.29 | 90 (R) | |
IC | 1 | 100 | 1.34 [0.89, 1.78] | NA | NA | |
Cell type | ||||||
NIHSS (3 months) | BM-MNCs | 3 | 188 | 0.57 [0.26, 0.89] | < 0.001a | 95 (R) |
MSC | 2 | 69 | − 0.07 [− 0.61, 0.47] | 0.79 | 82 (R) | |
BI (3 months) | BM-MNCs | 3 | 80 | 0.56 [− 1.63, 2.76] | 0.61 | 94 (R) |
MSC | 2 | 69 | 1.66 [− 1.91, 5.23] | 0.36 | 96 (R) | |
BI (6 months) | BM-MNCs | 5 | 300 | 1.24 [0.01, 2.48] | 0.05 | 95 (R) |
MSC | 2 | 69 | 1.08 [− 0.69, 2.84] | 0.23 | 87 (R) | |